Artificial Tears Study in Mild to Moderate Dry Eye Patients

Phase 2

Completed

• Conditions: Dry Eye
• Interventions: Drug: Systane; Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

• Registration Number: NCT00607776
• Lead Sponsor: Abbott Medical Optics

Brief Summary

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01
• Study Completion: 2007-04
• Study First Submitted: 2007-12-19
• Study First Submitted QC: 2008-02-05
• Study First Posted: 2008-02-06
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-31
• Last Update Posted: 2025-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• Mild to moderate dry eye
• over 18

Exclusion Criteria

• No concurrent ocular disease or meds

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Systane	Systane
2	(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400	Blink tears

Primary Outcome Measures

Name	Time	Method
Subjective ocular comfort	1 Month

Secondary Outcome Measures

Name	Time	Method
Vision quality	1 Month